Soligenix, Inc. Faces Delisting Concerns
Ticker: SNGX · Form: 8-K · Filed: Aug 15, 2025 · CIK: 812796
| Field | Detail |
|---|---|
| Company | Soligenix, Inc. (SNGX) |
| Form Type | 8-K |
| Filed Date | Aug 15, 2025 |
| Risk Level | high |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $2,500,000, $1,828,951, $1,439,300, $35 m, $500,000 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
Soligenix might get kicked off the exchange - big trouble.
AI Summary
Soligenix, Inc. filed an 8-K on August 15, 2025, reporting a notice of delisting or failure to meet continued listing standards. The company, previously known as Dor Biopharma Inc., Immunotherapeutics Inc., and Endorex Corp, is incorporated in Delaware and headquartered in Princeton, NJ.
Why It Matters
This filing indicates potential issues with Soligenix, Inc.'s ability to remain listed on its current exchange, which could impact its stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards is a severe event that directly threatens the company's public trading status.
Key Players & Entities
- Soligenix, Inc. (company) — Filer
- August 15, 2025 (date) — Filing Date
- Dor Biopharma Inc. (company) — Former Company Name
- Immunotherapeutics Inc. (company) — Former Company Name
- Endorex Corp (company) — Former Company Name
- 29 EMMONS DRIVE, SUITE B-10, PRINCETON, NJ 08540 (address) — Business and Mail Address
FAQ
What is the specific reason for Soligenix, Inc.'s notice of delisting or failure to meet continued listing standards?
The provided text of the 8-K filing does not specify the exact reason for the delisting notice, only that it is a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard'.
When was Soligenix, Inc. incorporated and in which state?
Soligenix, Inc. was incorporated in Delaware.
What were some of the previous names of Soligenix, Inc.?
Soligenix, Inc. was formerly known as Dor Biopharma Inc., Endorex Corp, and Immunotherapeutics Inc.
What is the business address of Soligenix, Inc.?
The business address of Soligenix, Inc. is 29 Emmons Drive, Suite B-10, Princeton, NJ 08540.
What is the SIC code for Soligenix, Inc.?
The Standard Industrial Classification (SIC) code for Soligenix, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 1,111 words · 4 min read · ~4 pages · Grade level 13 · Accepted 2025-08-15 17:17:20
Key Financial Figures
- $2,500,000 — intain stockholders' equity of at least $2,500,000 (the "Stockholders' Equity Requirement"
- $1,828,951 — ompany reported stockholders' equity of $1,828,951, which is below the Stockholders' Equit
- $1,439,300 — d total gross proceeds of approximately $1,439,300. Additionally, as of the date of this r
- $35 m — value of listed securities of at least $35 million, or net income of $500,000 from c
- $500,000 — at least $35 million, or net income of $500,000 from continuing operations in the most
Filing Documents
- sngx-20250815x8k.htm (8-K) — 42KB
- 0001558370-25-011619.txt ( ) — 161KB
- sngx-20250815.xsd (EX-101.SCH) — 4KB
- sngx-20250815_def.xml (EX-101.DEF) — 3KB
- sngx-20250815_lab.xml (EX-101.LAB) — 17KB
- sngx-20250815_pre.xml (EX-101.PRE) — 10KB
- sngx-20250815x8k_htm.xml (XML) — 5KB
01
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 15, 2025, Soligenix, Inc. (the "Company") received notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") advising the Company that it is not in compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholders' equity of at least $2,500,000 (the "Stockholders' Equity Requirement"). In the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, the Company reported stockholders' equity of $1,828,951, which is below the Stockholders' Equity Requirement for continued listing. This amount does not reflect sales activity under the Company's At-The-Market ("ATM") facility on July 1, 2025, which generated total gross proceeds of approximately $1,439,300. Additionally, as of the date of this report, the Company does not meet either of the alternative Nasdaq continued listing standards under the Nasdaq Listing Rules, market value of listed securities of at least $35 million, or net income of $500,000 from continuing operations in the most recently completed fiscal year, or in two of the three most recently completed fiscal years. The Notice has no immediate effect on the listing of the Company's common stock and the Company's common stock continues to trade on The Nasdaq Capital Market under the symbol "SNGX," subject to the Company's compliance with the other continued listing requirements. Pursuant to the Notice, Nasdaq has given the Company 45 calendar days, or until September 29, 2025, to submit to Nasdaq a plan to regain compliance. If the Company's plan is accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of the Notice to evidence compliance. The Company is currently evaluating various courses of action to regain complianc
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Soligenix, Inc. August 15, 2025 By: /s/ Christopher J. Schaber Christopher J. Schaber, Ph.D. President and Chief Executive Officer (Principal Executive Officer) 3